Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Initial clinical study with pyrazofurin

T Ohnuma, J F Holland

    Cancer Treatment Reports
    |May 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Pyrazofurin (PF) showed dose-limiting toxicity, primarily mucosal, in patients with carcinoma, lymphoma, and leukemia. While some breast cancer patients experienced partial responses, severe adverse events limited its use.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Putative protein markers in the sera of men with prostatic neoplasms.

    BJU international·2003
    Same author

    Stable lower PAR expression decreased DU145 prostate cancer cell growth in SCID mice.

    The Prostate·2001
    Same author

    High anticancer efficacy of L-proline-m-bis (2-chloroethyl) amino-L-phenylalanyl-L-norvaline ethyl ester hydrochloride (MF13) in vivo.

    Anticancer research·2001
    Same author

    Overexpression of deletion-mutant epidermal growth factor receptor is associated with altered genotoxic stress-provoked p53 mRNA induction in a human glioblastoma cell line.

    Anticancer research·2001
    Same author

    Detection of MMTV-like LTR and LTR-env gene sequences in human breast cancer.

    International journal of oncology·2001
    Same author

    MMTV-like env gene sequences in human breast cancer.

    Archives of virology·2001
    Same journal

    Rhabdomyolysis associated with high-dose cytarabine.

    Cancer treatment reports·1987
    Same journal

    Acute laryngeal edema after single-dose irradiation and doxorubicin.

    Cancer treatment reports·1987
    Same journal

    Timing may be a critical factor in drug therapy.

    Cancer treatment reports·1987
    Same journal

    Prednimustine in advanced malignant melanoma: a phase II study.

    Cancer treatment reports·1987
    Same journal

    Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    Same journal

    Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology
    • Clinical Trials

    Background:

    • Pyrazofurin (PF) is an antineoplastic agent evaluated for efficacy and toxicity.
    • Previous studies suggested potential activity but required careful dose management.

    Purpose of the Study:

    • To assess the safety, tolerability, and preliminary efficacy of pyrazofurin in patients with advanced solid tumors and hematologic malignancies.
    • To identify dose-limiting toxicities and establish maximum tolerated doses for different administration schedules.

    Main Methods:

    • Twenty-five patients with inoperable carcinoma and lymphoma received intravenous bolus PF (100-300 mg/m²).
    • Five acute leukemia patients received PF infusion (250-1500 mg/m²/144 hours).
    • Toxicity, response, and tolerability were monitored.

    Related Experiment Videos

    Main Results:

    • PF was tolerated at lower doses (100 mg/m² weekly bolus or 250 mg/m² every 2-3 weeks).
    • Higher infusion doses (750-1500 mg/m²/72-144 hours) caused severe, reversible mucocutaneous and hematologic toxicity.
    • Mucosal toxicity was dose-limiting; radiotherapy patients experienced more severe reactions.
    • Two breast cancer patients showed partial responses lasting 5 weeks and 1 month, respectively.

    Conclusions:

    • Pyrazofurin exhibits significant dose-limiting toxicities, particularly mucocutaneous and hematologic.
    • Careful dose and schedule selection are crucial for managing PF toxicity.
    • Limited efficacy was observed in some advanced cancers, warranting further investigation with optimized dosing strategies.